ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
IssuerBlackrock
ETF TickerBTEE(USD) LSE
ETF TickerBTEE.L(GBP) LSE

Holdings detail for ARCT

Stock NameArcturus Therapeutics Holdings Inc
TickerARCT(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS03969T1097

Show aggregate ARCT holdings

News associated with ARCT

Arcturus Therapeutics (NASDAQ:ARCT) Given New $54.00 Price Target at Leerink Partners
Arcturus Therapeutics (NASDAQ:ARCT – Free Report) had its price target cut by Leerink Partners from $63.00 to $54.00 in a report released on Friday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. ARCT has been the subject of a number of other reports. Canaccord Genuity Group decreased their target price on […] - 2025-08-25 02:12:53
Mitsubishi UFJ Asset Management Co. Ltd. Grows Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 9.2% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,693 shares of the biotechnology company’s stock after buying an additional 1,232 shares during […] - 2025-08-15 04:46:53
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Rating of “Buy” from Brokerages
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) have received an average rating of “Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued ratings on the stock […] - 2025-08-12 04:42:57
Empire Life Investments Inc. Sells 14,554 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Empire Life Investments Inc. trimmed its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 5.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 264,909 shares of the biotechnology company’s stock after selling 14,554 shares during the period. […] - 2025-08-04 04:44:57
Alps Advisors Inc. Trims Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Alps Advisors Inc. reduced its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 8.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,949 shares of the biotechnology company’s stock after selling 1,952 shares during the quarter. Alps Advisors Inc. owned approximately […] - 2025-07-18 04:49:09
Sumitomo Mitsui Trust Group Inc. Reduces Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Sumitomo Mitsui Trust Group Inc. reduced its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 6.7% in the first quarter, HoldingsChannel.com reports. The firm owned 1,926,084 shares of the biotechnology company’s stock after selling 138,966 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.07% of Arcturus Therapeutics […] - 2025-07-04 05:12:59
Arcturus Therapeutics (NASDAQ:ARCT) Stock Crosses Below 200 Day Moving Average – Time to Sell?
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $14.13 and traded as low as $13.74. Arcturus Therapeutics shares last traded at $14.41, with a volume of 517,333 shares changing hands. Wall Street Analyst […] - 2025-06-27 05:22:55
Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Scotiabank
Scotiabank began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage set a “sector outperform” rating and a $32.00 price target on the biotechnology company’s stock. Scotiabank’s price objective would suggest a potential upside of 151.37% from the company’s previous close. A […] - 2025-05-30 02:38:46
Cresset Asset Management LLC Sells 2,198 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Cresset Asset Management LLC decreased its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 16.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 11,511 shares of the biotechnology company’s stock after selling 2,198 shares during the period. Cresset Asset Management LLC’s holdings in […] - 2025-05-19 05:02:55
Arcturus Therapeutics (NASDAQ:ARCT) Given New $66.00 Price Target at Canaccord Genuity Group
Arcturus Therapeutics (NASDAQ:ARCT – Free Report) had its target price reduced by Canaccord Genuity Group from $68.00 to $66.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. ARCT has been the topic of a number of other research reports. HC Wainwright […] - 2025-05-14 04:58:54
Hsbc Holdings PLC Increases Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Hsbc Holdings PLC grew its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 11.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,368 shares of the biotechnology company’s stock after acquiring an additional 2,673 shares during the […] - 2025-05-08 06:07:00
Barclays PLC Lowers Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Barclays PLC trimmed its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 10.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 60,082 shares of the biotechnology company’s stock after selling 7,333 shares during the period. Barclays PLC’s holdings in Arcturus Therapeutics were worth $1,020,000 as of its most […] - 2025-05-06 04:38:59
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Holdings Lessened by Franklin Resources Inc.
Franklin Resources Inc. lessened its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 3.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 100,677 shares of the biotechnology company’s stock after selling 3,259 shares during the period. […] - 2025-04-15 05:32:54
Mitsubishi UFJ Asset Management Co. Ltd. Purchases 4,647 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 52.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,461 shares of the biotechnology company’s stock after acquiring an additional 4,647 […] - 2025-04-04 05:12:56
AlphaQuest LLC Sells 12,668 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
AlphaQuest LLC cut its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 63.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,142 shares of the biotechnology company’s stock after selling 12,668 shares during the period. AlphaQuest LLC’s holdings in […] - 2025-03-19 06:06:45
Arcturus Therapeutics (NASDAQ:ARCT) Given New $68.00 Price Target at Canaccord Genuity Group
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) had its price objective reduced by stock analysts at Canaccord Genuity Group from $74.00 to $68.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 414.76% […] - 2025-03-12 04:08:56
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below 200-Day Moving Average – Here’s Why
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $18.81 and traded as low as $16.51. Arcturus Therapeutics shares last traded at $16.69, with a volume of 364,852 shares. Wall Street Analysts Forecast Growth Several research […] - 2025-02-25 06:50:59
Spire Wealth Management Increases Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Spire Wealth Management increased its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 393.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,478 shares of the biotechnology company’s stock after buying an additional 10,746 shares during the […] - 2025-02-07 07:05:06

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) ARCT holdings

DateNumber of ARCT Shares HeldBase Market Value of ARCT SharesLocal Market Value of ARCT SharesChange in ARCT Shares HeldChange in ARCT Base ValueCurrent Price per ARCT Share HeldPrevious Price per ARCT Share Held
2025-12-18 (Thursday)20,777USD 133,596ARCT holding decreased by -1870USD 133,5960USD -1,870 USD 6.42999 USD 6.52
2025-12-17 (Wednesday)20,777ARCT holding decreased by -245USD 135,466ARCT holding decreased by -14421USD 135,466-245USD -14,421 USD 6.52 USD 7.13001
2025-12-16 (Tuesday)21,022ARCT holding decreased by -49USD 149,887ARCT holding decreased by -2878USD 149,887-49USD -2,878 USD 7.13001 USD 7.25001
2025-12-15 (Monday)21,071ARCT holding increased by 98USD 152,765ARCT holding decreased by -3694USD 152,76598USD -3,694 USD 7.25001 USD 7.46002
2025-12-12 (Friday)20,973USD 156,459ARCT holding decreased by -1258USD 156,4590USD -1,258 USD 7.46002 USD 7.52
2025-12-11 (Thursday)20,973ARCT holding increased by 98USD 157,717ARCT holding decreased by -2394USD 157,71798USD -2,394 USD 7.52 USD 7.66999
2025-12-10 (Wednesday)20,875USD 160,111ARCT holding increased by 9811USD 160,1110USD 9,811 USD 7.66999 USD 7.2
2025-12-09 (Tuesday)20,875USD 150,300ARCT holding decreased by -5219USD 150,3000USD -5,219 USD 7.2 USD 7.45001
2025-12-08 (Monday)20,875USD 155,519ARCT holding increased by 6680USD 155,5190USD 6,680 USD 7.45001 USD 7.13001
2025-12-05 (Friday)20,875USD 148,839ARCT holding increased by 6263USD 148,8390USD 6,263 USD 7.13001 USD 6.82999
2025-12-04 (Thursday)20,875ARCT holding increased by 980USD 142,576ARCT holding increased by 11468USD 142,576980USD 11,468 USD 6.82999 USD 6.59
2025-12-03 (Wednesday)19,895USD 131,108ARCT holding increased by 6764USD 131,1080USD 6,764 USD 6.59 USD 6.25001
2025-12-02 (Tuesday)19,895ARCT holding increased by 735USD 124,344ARCT holding decreased by -4USD 124,344735USD -4 USD 6.25001 USD 6.48998
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ARCT by Blackrock for IE00BDZVHG35

Show aggregate share trades of ARCT

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-12-17SELL-2457.2106.490 6.562USD -1,608 13.75 Profit of 1,760 on sale
2025-12-16SELL-497.3606.920 6.964USD -341 13.78 Profit of 334 on sale
2025-12-15BUY987.5287.115 7.156USD 701 13.81
2025-12-11BUY987.7597.465 7.494USD 734 13.87
2025-12-04BUY9806.8466.470 6.508USD 6,377 14.03
2025-12-02BUY7356.5006.070 6.113USD 4,493 14.10
2025-11-28BUY496.8956.745 6.760USD 331 14.18
2025-11-26BUY1476.8956.600 6.629USD 975 14.25
2025-11-26BUY1476.8956.600 6.629USD 975 14.25
2025-11-25BUY2456.8406.320 6.372USD 1,561 14.29
2025-11-24BUY496.3806.070 6.101USD 299 14.33
2025-11-20SELL-1966.3805.855 5.908USD -1,158 14.41 Profit of 1,666 on sale
2025-11-19BUY496.6906.020 6.087USD 298 14.45
2025-11-18BUY2946.8206.570 6.595USD 1,939 14.49
2025-11-17BUY987.3206.720 6.780USD 664 14.53
2025-11-14BUY497.6507.260 7.299USD 358 14.57
2025-11-12BUY498.6498.090 8.146USD 399 14.64
2025-11-10BUY489.0208.550 8.597USD 413 14.70
2025-11-06BUY488.6208.237 8.275USD 397 14.77
2025-11-04BUY499.4008.840 8.896USD 436 14.83
2025-10-30BUY2459.9809.410 9.467USD 2,319 14.92
2025-10-29BUY989.4409.944 9.893USD 970 14.95
2025-10-23SELL-18812.00012.100 12.090USD -2,273 15.04 Profit of 555 on sale
2025-10-20BUY9421.51022.600 22.491USD 2,114 14.98
2025-10-17BUY23520.66022.130 21.983USD 5,166 14.94
2025-10-15BUY37621.57022.220 22.155USD 8,330 14.91
2025-10-03BUY33622.56023.600 23.496USD 7,895 14.82
2025-10-02BUY4821.88021.940 21.934USD 1,053 14.78
2025-09-30BUY9618.43019.050 18.988USD 1,823 14.72
2025-09-26BUY9622.17022.400 22.377USD 2,148 14.66
2025-09-25BUY9620.31020.500 20.481USD 1,966 14.62
2025-09-18BUY4819.62019.690 19.683USD 945 14.59
2025-09-17BUY14418.05018.590 18.536USD 2,669 14.57
2025-09-11SELL-4818.04018.690 18.625USD -894 14.53 Loss of -197 on sale
2025-09-10BUY9617.99018.050 18.044USD 1,732 14.50
2025-07-17SELL-9413.54013.850 13.819USD -1,299 14.50 Profit of 64 on sale
2025-07-11SELL-38413.78014.440 14.374USD -5,520 14.53 Profit of 60 on sale
2025-07-02BUY2,64013.62014.090 14.043USD 37,074 14.54
2025-06-25BUY9613.95014.010 14.004USD 1,344 14.56
2025-06-11BUY9812.44013.320 13.232USD 1,297 14.72
2025-06-10BUY9812.90013.620 13.548USD 1,328 14.73
2025-06-04SELL-4912.26013.270 13.169USD -645 14.80 Profit of 80 on sale
2025-04-23BUY4812.65013.660 13.559USD 651 15.61
2025-04-10SELL-3849.3509.530 9.512USD -3,653 16.13 Profit of 2,540 on sale
2025-04-08SELL-498.9109.460 9.405USD -461 16.28 Profit of 337 on sale
2025-04-07SELL-499.0909.130 9.126USD -447 16.37 Profit of 355 on sale
2025-04-04SELL-2459.1109.350 9.326USD -2,285 16.45 Profit of 1,746 on sale
2025-04-01BUY1969.43010.490 10.384USD 2,035 16.61
2025-03-31SELL-14710.59011.240 11.175USD -1,643 16.68 Profit of 810 on sale
2025-03-21BUY1,71412.88012.930 12.925USD 22,153 17.02
2025-03-14SELL-68814.08014.290 14.269USD -9,817 17.26 Profit of 2,058 on sale
2025-03-07SELL-8614.55015.400 15.315USD -1,317 17.50 Profit of 188 on sale
2025-03-04SELL-4315.49015.950 15.904USD -684 17.58 Profit of 72 on sale
2025-02-25BUY8616.06016.940 16.852USD 1,449 17.70
2025-02-19SELL-4317.32017.610 17.581USD -756 17.74 Profit of 7 on sale
2025-02-13BUY12616.41016.460 16.455USD 2,073 17.75
2025-02-12BUY4215.86016.400 16.346USD 687 17.79
2025-02-11BUY16816.07016.250 16.232USD 2,727 17.83
2024-12-30SELL-1,86316.58016.910 16.877USD -31,442 18.31 Profit of 2,663 on sale
2024-11-18SELL-70516.27017.370 17.260USD -12,168 18.99 Profit of 1,221 on sale
2024-11-08SELL-4719.63019.930 19.900USD -935 18.91 Loss of -47 on sale
2024-10-21SELL-4820.88021.200 21.168USD -1,016 0.00 Loss of -1,016 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ARCT

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19263,050654445,27659.1%
2025-09-18243,055128528,08646.0%
2025-09-17153,5060239,67364.0%
2025-09-16168,941250384,53643.9%
2025-09-1581,7420158,51551.6%
2025-09-12147,7100262,85556.2%
2025-09-1199,5863,939173,74857.3%
2025-09-1082,21610142,60757.7%
2025-09-0996,67911151,44463.8%
2025-09-0883,37725159,52752.3%
2025-09-0587,7591183,08647.9%
2025-09-0484,27191145,29658.0%
2025-09-0372,0681141,17451.0%
2025-09-0239,080082,14747.6%
2025-08-2980,961257179,95945.0%
2025-08-2888,08998225,06839.1%
2025-08-2738,893086,06045.2%
2025-08-2628,8122094,45430.5%
2025-08-2548,8361,396130,33837.5%
2025-08-2263,14622161,24039.2%
2025-08-2171,2331,783200,63635.5%
2025-08-2088,9681205,86843.2%
2025-08-19124,2191,874282,77643.9%
2025-08-18349,598677543,67664.3%
2025-08-15182,9676365,20550.1%
2025-08-14296,71319,441723,75541.0%
2025-08-13320,8312,493788,74940.7%
2025-08-12344,7022,010749,29646.0%
2025-08-11147,0710479,08130.7%
2025-08-0888,4380154,47357.3%
2025-08-0767,88630120,28656.4%
2025-08-0689,15730150,30759.3%
2025-08-0565,36440123,32353.0%
2025-08-0454,4070108,26250.3%
2025-08-0179,124113125,15963.2%
2025-07-3174,466225148,21650.2%
2025-07-3075,71019,477219,17134.5%
2025-07-29201,6942,041281,19271.7%
2025-07-2842,509176109,53338.8%
2025-07-25111,4041,103158,92070.1%
2025-07-2434,55151493,84936.8%
2025-07-2385,6542,416153,96355.6%
2025-07-2244,8060104,40542.9%
2025-07-2146,543095,17648.9%
2025-07-1843,13910284,12851.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy